FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis- click HERE to read more!
Could New CBD Cream Could Be Ultimate Cure For Acne?
Psoriasis is not a cosmetic problem. Nearly 60 percent of people with psoriasis reported their disease to be a large problem in their everyday life. DS Research is currently conducting various research studies for the treatment of plaque psoriasis as well as itching that is associated with psoriasis. To learn more about these statistics involving… Read More
In recent years, research into other autoimmune diseases brought new insights about the immune system. It turns out that some of the problems in those conditions are active in psoriasis, as well. The new info brought treatments that target specific areas of your immune system. Called biologics, these drugs launched a new era of psoriasis… Read More
Click HERE to read more!
Eskata approved for the treatment of patients with Seborrheic Keratoses that are raised. To read more click HERE
TREMFYA™ is the first and only biologic approved that selectively blocks interleukin (IL)-23. Seven out of ten patients receiving TREMFYA™ achieved at least 90 percent improvement in skin clearance at week 16. Nearly three quarters of TREMFYA™-treated patients demonstrated at least 90 percent clearer skin at week 48. TREMFYA™ demonstrated superior results in skin clearance… Read More
March 28, 2017 – Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD) for whom other topical treatments have not worked or are not adv
“Guselkumab Beats Adalimumab for Moderate to Severe Psoriasis”. DS Research has conducted various trials for psoriasis medications. Be sure to check our this article about the effectiveness of Guselkumab for moderate to severe psoriasis. Click here.
Get your beauty sleep! The ZZZs you catch every night can have a profound impact on your skin health. Here’s how.